- Free from Publisher V Bril, RA Buchanan - Diabetes Care, 2006 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Patients with mild to moderate DSP, as determined
by the presence of sural nerve responses, were enrolled in a double-blind,
placebo-controlled biopsy trial and randomized to placebo or 5 or 20 mg/day ... Cited by 44 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org N Hotta, Y Akanuma, R Kawamori, K Matsuoka, … - Diabetes Care, 2006 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Subjects with diabetic neuropathy, median motor
nerve conduction velocity (MNCV) ≥40 m/s, and HbA 1c ≤9% were enrolled in
this open-label, multicenter study and randomized to 150 mg/day epalrestat ... Cited by 46 - Related articles - BL Direct - All 5 versions
AI Vinik, V Bril, P Kempler, WJ Litchy, S … - Clinical therapeutics, 2005 - Elsevier Patients were enrolled in a multinational, randomized, Phase II, double-blind,
placebo-controlled parallel-group trial comparing 32 mg/d or 64 mg/d RBX with
placebo for 1 year. DPN was identified by abnormal measurable vibration ... Cited by 44 - Related articles - All 3 versions
- Free from Publisher V Bril, RA Buchanan - Diabetes Care, 2004 - Am Diabetes Assoc OBJECTIVE—The primary purpose of this investigation was to determine whether
AS-3201, a new aldose reductase inhibitor, penetrates the sural nerve and
inhibits sorbitol and fructose accumulation in patients with diabetic ... Cited by 48 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org JK Clifft, RJ Kasser, TS Newton, AJ Bush - Diabetes Care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In this randomized, double-blind,
placebo-controlled study, 39 subjects with diabetic peripheral neuropathy
completed the 8-week study. Subjects received 30 min of active or placebo ... Cited by 27 - Related articles - BL Direct - All 7 versions
- Free from Publisher N Hotta, T Toyota, K Matsuoka, Y Shigeta, R … - Diabetes Care, 2001 - cat.inist.fr OBJECTIVE The purpose of this study was to evaluate the efficacy of fidarestat,
a novel aldose reductase BAR) inhibitor, in a double-blind placebo controlled
study in patients with type 1 and type 2 diabetes and associated peripheral ... Cited by 63 - Related articles - BL Direct - All 5 versions
- ►bolecina.com [PDF] L Reichstein, S Labrenz, D Ziegler, S Martin - Diabetologia, 2005 - Springer Abstract Aims/hypothesis: Diabetic distal symmetrical sensory polyneuropathy
(DSP) affects 20–30% of diabetic patients. Transcutaneouselectricalnerve
stimulation(TENS) and electrical spinal cord stimulation have been proposed ... Cited by 21 - Related articles - All 7 versions
DV Coppini, PA Bowtell, C Weng, PJ Young, … - Journal of clinical epidemiology, 2000 - Elsevier Diabetic subjects still have a reduced life expectancy despite many potential
advances in patient care. Furthermore, population-based studies in well-defined
cohorts of patients, to investigate the reduced life expectancies, are ... Cited by 44 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org D Ziegler, A Ametov, A Barinov, PJ Dyck, I … - Diabetes Care, 2006 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In this multicenter, randomized, double-blind,
placebo-controlled trial, 181 diabetic patients in Russia and Israel received
once-daily oral doses of 600 mg (n = 45) (ALA600), 1,200 mg (n = 47) ... Cited by 97 - Related articles - BL Direct - All 6 versions
- ►oxfordjournals.org MW Powell, DH Carnegie, TJ Burke - Age and ageing, 2006 - Br Geriatrics Soc Objective: to determine whether restoration of sensation, impaired due to
diabetic peripheral neuropathy (DPN), would reduce the number of falls and the
fear of falling and improve activities of daily living (ADL) in a ... Cited by 11 - Related articles - BL Direct - All 11 versions
